Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.08. | Cullinan Oncology stock gets Buy rating from H.C. Wainwright ahead of WCLC data | 2 | Investing.com | ||
CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
21.08. | Cullinan Oncology: H.C. Wainwright startet Coverage mit "Buy" vor wichtigen Studiendaten | 3 | Investing.com Deutsch | ||
07.08. | Cullinan Therapeutics GAAP EPS of -$1.07 | 2 | Seeking Alpha | ||
07.08. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.08. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | 134 | GlobeNewswire (Europe) | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
07.08. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
03.07. | Cullinan Oncology stock rating reiterated at Buy by Clear Street | 10 | Investing.com | ||
12.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
05.06. | Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio | 1 | Contract Pharma | ||
04.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | 147 | GlobeNewswire (Europe) | Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with... ► Artikel lesen | |
04.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.05. | Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.: Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 | 1 | GlobeNewswire (USA) | ||
08.05. | Cullinan Therapeutics GAAP EPS of -$0.74 beats by $0.07 | 1 | Seeking Alpha | ||
08.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
08.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | 810 | GlobeNewswire (Europe) | Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's... ► Artikel lesen | |
29.04. | Cullinan Therapeutics startet Studie zur Sjögren-Krankheit | 2 | Investing.com Deutsch | ||
23.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, ... | 1 | GlobeNewswire (USA) | ||
16.04. | Cullinan Therapeutics Wins EMA Approval To Launch CLN-978 Trial In Rheumatoid Arthritis | 1 | RTTNews | ||
16.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid ... | 180 | GlobeNewswire (Europe) | Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
BIONTECH | 87,40 | +2,10 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
QIAGEN | 40,400 | +1,74 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
ADMA BIOLOGICS | 17,255 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,480 | -1,96 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
ARCELLX | 69,43 | -1,17 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
BEAM THERAPEUTICS | 16,350 | -2,97 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen |